Avadel Pharmaceuticals (AVDL) Price & Analysis

Compare

755 Followers

AVDL Stock Chart & Stats

Day’s Range― - ―

52-Week Range$6.38 - $16.66

Previous CloseN/A

Volume358.54K

Average Volume (3M)1.23M

Market Cap

$1.44B

Enterprise Value$833.42M

Total Cash (Recent Filing)$81.55M

Total Debt (Recent Filing)$2.73M

Price to Earnings (P/E)―

Beta1.07

Next Earnings

Nov 05, 2025

EPS Estimate

0.08

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.10

Shares Outstanding97,097,640

10 Day Avg. Volume1,247,331

30 Day Avg. Volume1,231,946

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.58

Enterprise Value/Revenue3.77

Enterprise Value/Gross Profit4.21

Enterprise Value/Ebitda125.48

Forecast

1Y Price Target

$18.88

Price Target Upside27.14% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Product DevelopmentThe FDA granted Orphan Drug Designation to Lumryz, highlighting its potential major contribution to patient care.

Revenue ForecastThe revenue guidance for the fiscal year was raised to $265-275M, indicating confidence in continued growth.

Sales PerformanceAvadel reported strong sales of its marketed product LUMRYZ for treatment of narcolepsy, leading to a 64% growth compared to the previous year.

Bears Say

Investor SentimentAvadel's current stock price reflects excessively conservative investor sentiment, underrating the market opportunity for LUMRYZ in narcolepsy and its potential in idiopathic hypersomnia.

Market CompetitionAvadel's competition may fragment further as the leading purveyor of branded oxybate products shifts focus to other therapeutic areas.

Avadel Pharmaceuticals News

Avadel Pharmaceuticals price target raised to $20 from $13 at UBS

UBS analyst Ashwani Verma raised the firm’s price target on Avadel Pharmaceuticals (AVDL) to $20 from $13 and...

7d ago

AVDL

Avadel Pharmaceuticals price target raised to $18 from $16 at Deutsche Bank

Deutsche Bank raised the firm’s price target on Avadel Pharmaceuticals (AVDL) to $18 from $16 and keeps a...

20d ago

AVDL

Avadel Pharmaceuticals price target raised to $24 from $22 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Avadel Pharmaceuticals (AVDL) to $24 from $22 and keeps a...

20d ago

AVDL

Avadel Pharmaceuticals reports Q2 EPS 10c, consensus 3c

Reports Q2 revenue $68.129M, consensus $60.28M. “LUMRYZ strengthened its market position and delivered accelerated growth in revenue, positive...

21d ago

AVDL

Avadel Pharmaceuticals sees FY25 revenue $265M-$275M, consensus $260.01M

Raising 2025 full year revenue guidance to $265- $275 million. Published first on TheFly – the ultimate source...

21d ago

AVDL

Avadel Pharmaceuticals sees Q3 revenue $71M-$75M, consensus $70.61M

Providing guidance for the quarter ending September 30, 2025 of $71 – $75 million in net product revenue...

21d ago

AVDL

Avadel Pharmaceuticals Reports Strong Earnings and Growth

Avadel Pharmaceuticals (($AVDL)) has held its Q2 earnings call. Read on for the main highlights of the call....

17d ago

AVDL

Avadel Pharmaceuticals Reports Strong Q2 Growth

Avadel Pharmaceuticals ( ($AVDL) ) has released its Q2 earnings. Here is a breakdown of the information Avadel...

20d ago

AVDL

AVDL Earnings this Week: How Will it Perform?

Avadel Pharmaceuticals (AVDL) is scheduled to report 2nd quarter earnings on 08/07/2025, before the market opens. Regarding Q2...

23d ago

AVDL

Avadel Pharmaceuticals Elects New Board and Auditor

Avadel Pharmaceuticals ( ($AVDL) ) has issued an announcement. On July 29, 2025, Avadel Pharmaceuticals held its Annual...

30d ago

AVDL

Avadel Pharmaceuticals assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju assumed coverage of Avadel Pharmaceuticals (AVDL) with a Buy rating and $22 price...

1M ago

AVDL

Avadel announces appeals court decision upholding FDA approval of LUMRYZ

Avadel Pharmaceuticals (AVDL) announced that, on Friday, June 27, 2025, the U.S. Court of Appeals for the District...

2M ago

AVDL

JAZZ

Avadel Under Fire as Activist Investor Seeks to Unthrone the Board

Avadel Pharmaceuticals ($AVDL) is facing mounting pressure from activist investor ASL Strategic Value, which has launched a challenge...

2M ago

AVDL

Avadel Pharmaceuticals Wins Appeal on LUMRYZ Approval

The latest update is out from Avadel Pharmaceuticals ( ($AVDL) ). On June 22, 2023, Jazz Pharmaceuticals filed...

2M ago

AVDL

AVDL FAQ

What was Avadel Pharmaceuticals’s price range in the past 12 months?

Avadel Pharmaceuticals lowest stock price was $6.38 and its highest was $16.66 in the past 12 months.

What is Avadel Pharmaceuticals’s market cap?

Avadel Pharmaceuticals’s market cap is $1.44B.

When is Avadel Pharmaceuticals’s upcoming earnings report date?

Avadel Pharmaceuticals’s upcoming earnings report date is Nov 05, 2025 which is in 69 days.

How were Avadel Pharmaceuticals’s earnings last quarter?

Avadel Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported $0.1 earnings per share for the quarter, beating the consensus estimate of $0.031 by $0.069.

Is Avadel Pharmaceuticals overvalued?

According to Wall Street analysts Avadel Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Avadel Pharmaceuticals pay dividends?

Avadel Pharmaceuticals does not currently pay dividends.

What is Avadel Pharmaceuticals’s EPS estimate?

Avadel Pharmaceuticals’s EPS estimate is 0.08.

How many shares outstanding does Avadel Pharmaceuticals have?

Avadel Pharmaceuticals has 97,097,640 shares outstanding.

What happened to Avadel Pharmaceuticals’s price movement after its last earnings report?

Avadel Pharmaceuticals reported an EPS of $0.1 in its last earnings report, beating expectations of $0.031. Following the earnings report the stock price went up 14.775%.

Which hedge fund is a major shareholder of Avadel Pharmaceuticals?

Currently, no hedge funds are holding shares in AVDL

Avadel Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-3.63%

Trailing 12-Months

Asset Growth

18.81%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Avadel Pharmaceuticals

Avadel Pharmaceuticals (AVDL) is a biopharmaceutical company focused on developing and commercializing innovative therapies to treat various sleep disorders and other conditions. The company operates primarily in the pharmaceutical sector, specializing in the formulation and delivery of medications that enhance patient outcomes. Avadel's core products include its proprietary drug delivery technologies and a portfolio of approved medications aimed at improving sleep quality and managing related health issues.

Avadel Pharmaceuticals (AVDL) Earnings & Revenues

Historic Earnings Reports

AVDL Company Deck

AVDL Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a positive sentiment with significant growth in patient demand, strong financial performance, and successful litigation outcomes. Although there are some concerns regarding pending royalty determinations and increased operating expenses, the positive aspects significantly outweigh the lowlights, indicating a strong position for future growth.View all AVDL earnings summaries

AVDL Stock 12 Month Forecast

Average Price Target

$18.88

▲(27.14% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","25":"$25","10.75":"$10.75","15.5":"$15.5","20.25":"$20.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,10.75,15.5,20.25,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.08,12.073846153846153,13.067692307692308,14.061538461538461,15.055384615384614,16.049230769230768,17.043076923076924,18.036923076923078,19.03076923076923,20.024615384615384,21.018461538461537,22.012307692307694,23.006153846153843,{"y":24,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.08,11.68,12.28,12.879999999999999,13.48,14.079999999999998,14.68,15.28,15.879999999999999,16.479999999999997,17.08,17.68,18.279999999999998,{"y":18.88,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.08,11.458461538461538,11.836923076923076,12.215384615384615,12.593846153846155,12.972307692307693,13.350769230769231,13.72923076923077,14.107692307692307,14.486153846153847,14.864615384615384,15.243076923076924,15.621538461538462,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.51,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.17,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.16,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.05,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.59,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.51,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.91,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.51,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.61,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.81,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.08,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >